CN106262935A - 一种儿童型钙铁锌硒多肽粉 - Google Patents
一种儿童型钙铁锌硒多肽粉 Download PDFInfo
- Publication number
- CN106262935A CN106262935A CN201610640368.3A CN201610640368A CN106262935A CN 106262935 A CN106262935 A CN 106262935A CN 201610640368 A CN201610640368 A CN 201610640368A CN 106262935 A CN106262935 A CN 106262935A
- Authority
- CN
- China
- Prior art keywords
- calcium
- zinc
- mixture
- selenium
- lactose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052711 selenium Inorganic materials 0.000 title claims abstract description 44
- 239000011669 selenium Substances 0.000 title claims abstract description 44
- 239000000843 powder Substances 0.000 title claims abstract description 26
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 21
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 16
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 16
- 229940091258 selenium supplement Drugs 0.000 claims abstract description 43
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims abstract description 16
- 229960001471 sodium selenite Drugs 0.000 claims abstract description 16
- 239000011781 sodium selenite Substances 0.000 claims abstract description 16
- 235000015921 sodium selenite Nutrition 0.000 claims abstract description 16
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims abstract description 12
- 239000004227 calcium gluconate Substances 0.000 claims abstract description 12
- 229960004494 calcium gluconate Drugs 0.000 claims abstract description 12
- 235000013927 calcium gluconate Nutrition 0.000 claims abstract description 12
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 12
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 claims abstract description 11
- 239000004225 ferrous lactate Substances 0.000 claims abstract description 11
- 229940037907 ferrous lactate Drugs 0.000 claims abstract description 11
- 235000013925 ferrous lactate Nutrition 0.000 claims abstract description 11
- 229960000306 zinc gluconate Drugs 0.000 claims abstract description 11
- 239000011670 zinc gluconate Substances 0.000 claims abstract description 11
- 235000011478 zinc gluconate Nutrition 0.000 claims abstract description 11
- 108010001441 Phosphopeptides Proteins 0.000 claims abstract description 10
- 229940071162 caseinate Drugs 0.000 claims abstract description 10
- 230000008569 process Effects 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 33
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 27
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 18
- 239000008101 lactose Substances 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 13
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 10
- MKJXYGKVIBWPFZ-CEOVSRFSSA-L calcium;(2s)-2-hydroxypropanoate Chemical compound [Ca+2].C[C@H](O)C([O-])=O.C[C@H](O)C([O-])=O MKJXYGKVIBWPFZ-CEOVSRFSSA-L 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 8
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 7
- 239000005018 casein Substances 0.000 claims description 6
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 6
- 235000021240 caseins Nutrition 0.000 claims description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 5
- 210000000481 breast Anatomy 0.000 claims description 4
- 238000007689 inspection Methods 0.000 claims description 3
- 241000209051 Saccharum Species 0.000 claims 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract description 32
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 31
- 229960005069 calcium Drugs 0.000 abstract description 31
- 239000011575 calcium Substances 0.000 abstract description 31
- 229910052791 calcium Inorganic materials 0.000 abstract description 31
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 abstract description 25
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract description 20
- 239000011701 zinc Substances 0.000 abstract description 20
- 229910052725 zinc Inorganic materials 0.000 abstract description 20
- 230000012010 growth Effects 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 4
- 239000013589 supplement Substances 0.000 abstract description 2
- 239000011573 trace mineral Substances 0.000 abstract description 2
- 235000013619 trace mineral Nutrition 0.000 abstract description 2
- 238000010521 absorption reaction Methods 0.000 description 20
- 230000000694 effects Effects 0.000 description 10
- 229930003316 Vitamin D Natural products 0.000 description 9
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 9
- 235000019166 vitamin D Nutrition 0.000 description 9
- 239000011710 vitamin D Substances 0.000 description 9
- 150000003710 vitamin D derivatives Chemical class 0.000 description 9
- 229940046008 vitamin d Drugs 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 2
- 229910000640 Fe alloy Inorganic materials 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- KFZAUHNPPZCSCR-UHFFFAOYSA-N iron zinc Chemical compound [Fe].[Zn] KFZAUHNPPZCSCR-UHFFFAOYSA-N 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000014860 sensory perception of taste Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 208000019926 Keshan disease Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 206010039921 Selenium deficiency Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- CPGKMLVTFNUAHL-UHFFFAOYSA-N [Ca].[Ca] Chemical compound [Ca].[Ca] CPGKMLVTFNUAHL-UHFFFAOYSA-N 0.000 description 1
- XYUNNDAEUQFHGV-UHFFFAOYSA-N [Se].[Se] Chemical compound [Se].[Se] XYUNNDAEUQFHGV-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- QNDQILQPPKQROV-UHFFFAOYSA-N dizinc Chemical compound [Zn]=[Zn] QNDQILQPPKQROV-UHFFFAOYSA-N 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical class O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 1
- SBIBMFFZSBJNJF-UHFFFAOYSA-N selenium;zinc Chemical compound [Se]=[Zn] SBIBMFFZSBJNJF-UHFFFAOYSA-N 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000002356 skeleton Anatomy 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开一种儿童型钙铁锌硒多肽粉,按重量份数计包括以下组分:葡萄糖酸钙28.5‑56.7份,乳酸亚铁0.2‑0.4份,葡萄糖酸锌0.36‑0.64份,亚硒酸钠0.000255‑0.00036份,酪蛋白磷酸肽0.1‑1.0份。该配方不仅有效地为儿童补充身体必需的钙、铁、锌、硒,还可以解决儿童在生长发育过程中遇到的多种微量元素同时缺乏的问题。
Description
技术领域
本发明属于保健食品技术领域,特别涉及一种儿童型钙铁锌硒多肽粉。
背景技术
钙是人体所不可或缺的营养素之一,是人体生命源。钙是构成人体骨骼和牙齿的主要成分,且在维持人体循环、呼吸、神经、内分泌、消化、血液、肌肉、骨骼、泌尿、免疫等各系统正常生理功能中起重要调节作用。维持人体所有细胞的正常生理状态,都要依赖钙的存在。可以说,人体没有任何系统的功能与钙无关,钙代谢平衡对于维持生命和健康起到至关重要的作用。每天摄入足够钙量,才能维持人体正常的新陈代谢,增强人体对生活环境的适应力。儿童正处于骨骼和牙齿生长发育的重要时期,如果缺钙将会导致腿软、抽筋、痉挛、乏力;偏食、厌食;蛀牙、牙齿发育不良;发育迟缓、身高不足等。
铁是人体必需元素之一,是人体血红细胞形成的重要成分,能提高红细胞携氧量、促进体内氧运输和细胞呼吸,对维持人体正常的免疫功能、保持人的良好记忆和思维活动起重要作用。儿童由于处于快速成长期,对铁的需求量相对很大,普通饮食难以满足人体对铁的需求,故特别容易出现铁营养不良,会导致缺铁性贫血、抵抗力下降、面色苍白、手脚发凉、精神不振、不爱活动、食欲减退、发育迟缓,反应迟钝、体重较轻等。
锌存在于众多的酶系中,是人体内200多种酶的组成部分,如碳酸酐酶、呼吸酶、乳酸脱氢酸、超氧化物歧化酶、碱性磷酸酶、DNA和RNA聚合酶等,是核酸、蛋白质、碳水化合物的合成和维生素A利用的必需物质。锌具有促进生长发育、改善味觉、维持正常免疫功能、维护正常骨骼的骨化、参与生殖器官的发育和正常功能的维持、促进组织再生、有利伤口愈合、保护皮肤健康等作用。儿童缺锌会导致味觉嗅觉差、厌食、偏食或异食、生长发育不良、免疫力下降、智力发育落后等。
硒是人体必需的15种营养素之一,硒具有抗癌、抗氧化、增强免疫力、拮抗有害重金属、调节多种维生素的吸收与利用、调节蛋白质的合成等作用,被科学家称之为人体微量元素中的“防癌之王”。世界40多个国家处于缺硒地区,中国22个省份的几亿人口都处于缺硒或低硒地带,这些地区的人口肿瘤、肝病、心血管疾病等发病率很高。硒缺乏最明显的病症是克山病,主要发生于2~6岁儿童,主要症状表现为:疲劳乏力、心慌、面色苍白、心跳加快,甚至发生休克、心力衰竭、心律失常。缺硒还可导致大骨节病、甲状腺肿、免疫力下降、智力发育迟缓、龋齿等。
目前,应用较为广泛的钙吸收剂是维生素D,维生素D作为传统的钙吸收剂,存在以下缺陷:1)维生素D只是单纯地促进钙的吸收,对铁和锌的吸收会造成一定的不利影响;2)维生素D的作用受年龄和钙摄入量的影响;3)维生素D摄入过量会对肾和骨造成一定的危害。为克服维生素D作为钙吸收剂的缺陷,本发明提供了一种儿童型钙铁锌硒多肽粉。
发明内容
本发明目的是提供一种儿童型钙铁锌硒多肽粉,突破现有产品难吸收、利用率低、易上火便秘、易伤肠胃等缺陷,不仅有效地为儿童补充身体必需的钙、铁、锌、硒,还可以解决儿童在生长发育过程中遇到的多种微量元素同时缺乏的问题。
本发明采用的技术方案为:
一种儿童型钙铁锌硒多肽粉,按重量份数计包括以下组分:
所述的一种儿童型钙铁锌硒多肽粉的制备,按重量份数计还包括甜橙粉0.1-2.0份,柠檬酸0.5-2.0份,白砂糖40-80份,乳糖0.1-2.0份。
所述的一种儿童型钙铁锌硒多肽粉的制备,按重量份数计还包括L-乳酸钙0.9-1.7份。
一种所述的儿童型钙铁锌硒多肽粉的制备方法,包括步骤如下:
1)原辅料的处理,将葡萄糖酸钙、L-乳酸钙、葡萄糖酸锌、乳酸亚铁、酪蛋白磷酸肽、乳糖、白砂糖、柠檬酸、甜橙粉分别过100目筛,备用;
2)混合:在室内湿度为45-65%的条件下,先将亚硒酸钠和乳糖按配方量以等量递增法混合,得混合物A;再将混合物A与配方量的葡萄糖酸锌、L-乳酸钙、乳酸亚铁、酪蛋白磷酸肽、柠檬酸、甜橙粉混合20-40分钟,得混合物B;然后将混合物B与配方量的葡萄糖酸钙、白砂糖混合20-40min,得总混合物;
3)将混合物进行分装、包装入袋、经成品检验合格后入库。
所述的制备方法,步骤2)中亚硒酸钠和乳糖的混合具体为:取与亚硒酸钠等量的乳糖与亚硒酸钠混合均匀,得第一次混合物;再取与第一次混合物等量的乳糖与第一次混合物混合均匀,得第二次混合物;如此倍量增加,直至亚硒酸钠与乳糖全部混合均匀,得混合物A。
本发明具有以下有益效果:
本发明以葡萄糖酸钙、乳酸亚铁、葡萄糖酸锌、亚硒酸钠为有机钙铁锌硒源,能与酪蛋白磷酸肽科学完美结合,形成稳定的“酪蛋白磷酸肽有机钙铁锌硒结合体”,这种“酪蛋白磷酸肽有机钙铁锌硒结合体”具有以下突出的优点:1、能直接进入肠粘膜细胞而被机体利用,不会相互排斥,不会影响吸收;2、其亲和力是其他组织的7倍以上,大大提高了人体对钙铁锌硒的利用率;3、其分子结构稳定,不会被胃酸、食物中的植物酸、草酸、碱性物质等破坏;4、其性能纯正温和,在pH值1-14任何环境范围下均充分溶解,溶解时不消耗胃酸,不伤肠胃,不会引起上火、消化不良、便秘等副作用,因此在不同体质的儿童体内都能被很好地吸收。
此外,本发明还具有以下优点:选用以牛乳酪蛋白为原料的酪蛋白磷酸肽(CPP),其是通过生物技术制得的具有生物活性的多肽,即使超量服用也不会对人体产生任何毒副作用。CPP具有在很宽的pH范围内完全溶解的特性,可耐受高温处理,具有良好的稳定性,即使在人体肠道内pH呈中性到弱碱性的环境中,CPP能螯合钙、铁、锌离子,保护其不被膳食中的磷酸、草酸、植酸等阴离子沉淀,从而有效促进对钙、铁、锌等的吸收和利用。此外,CPP添加于食品时,具有低量高效的特点,添加CPP的制品可保持原有的风味和口感。酪蛋白磷酸肽还具有固齿、健齿、修复龈齿的作用。本发明中添加了甜橙粉,甜橙酸甜果味更适合儿童口味,且未添加任何色素和防腐剂,食用安全。本发明产品适宜人群:需要补充钙、铁、锌、硒的4-10岁儿童。
具体实施方式
实施例1一种儿童型钙铁锌硒多肽粉
一、分别准确称取葡萄糖酸钙42.5kg、L-乳酸钙1kg,乳酸亚铁0.3797kg、葡萄糖酸锌0.57kg、亚硒酸钠0.0003kg、酪蛋白磷酸肽0.5kg、甜橙粉0.55kg、柠檬酸1.5kg、白砂糖51.5kg、乳糖1.5kg。
二、制备方法如下:
1)原辅料的处理,将葡萄糖酸钙、L-乳酸钙、葡萄糖酸锌、乳酸亚铁、酪蛋白磷酸肽、乳糖、白砂糖、柠檬酸、甜橙粉分别过100目筛,备用;
2)混合:在室内湿度为45-65%的条件下,先将亚硒酸钠和乳糖按配方量以等量递增法混合(即取与亚硒酸钠等量的乳糖与亚硒酸钠混合均匀,得第一次混合物;再取与第一次混合物等量的乳糖与第一次混合物混合均匀,得第二次混合物;如此倍量增加,直至亚硒酸钠与乳糖全部混合均匀),得混合物A。再将混合物A与配方量的葡萄糖酸锌、L-乳酸钙、乳酸亚铁、酪蛋白磷酸肽、柠檬酸、甜橙粉混合20-40分钟,得混合物B;然后将混合物B与配方量的葡萄糖酸钙、白砂糖混合20-40min,得总混合物;
3)将混合物进行分装、包装入袋(净含量/规格:5g/包),经成品检验合格后入库。
三、感官评定:
取5克本实施例产品,加入到40ml 50℃的温开水中,完全溶解。选取10位感官评定人员,观察品尝后,按照表1评定方法对本发明产品的色泽、状态、滋、气味进行全面评价,取平均分作为综合评分。
表1感官评定方法和结果
由表1得出感官评定结论:本发明产品色泽为乳白色,均匀一致,粉末状、无结块、无肉眼可见外来杂质,口感酸甜,滋味宜人,无异味。
实施例2对比实验
实验动物:昆明小鼠,4~5周龄,18~22g,24只,雄性。
根据体重随机对实验动物分成三组,每组8只小鼠:
Ⅰ:以550mg/天葡萄糖酸钙+7mg/天葡萄糖酸锌+5mg/天乳酸亚铁+5.5μg/天亚硒酸钠灌注小鼠。
Ⅱ:以550mg/天葡萄糖酸钙+7mg/天葡萄糖酸锌+5mg/天乳酸亚铁+5.5μg/天亚硒酸钠+6.5μg/天维生素D灌注小鼠。
Ⅲ:以550mg/天葡萄糖酸钙+7mg/天葡萄糖酸锌+5mg/天乳酸亚铁+5.5μg/天亚硒酸钠+6.5mg/天酪蛋白磷酸肽灌注小鼠。
小鼠平衡饲养后,按以上分组方案预饲养一周后,分别收集每只受试动物的粪3天,测定摄入钙、铁、锌、硒量和粪中的钙、铁、锌、硒量,结果如表2-5所示。按下式计算:
吸收钙=摄入钙-粪钙 钙吸收率=(吸收钙/摄入钙)×100%
吸收铁=摄入铁-粪铁 铁吸收率=(吸收铁/摄入铁)×100%
吸收锌=摄入锌-粪锌 锌吸收率=(吸收锌/摄入锌)×100%
吸收硒=摄入硒-粪硒 硒吸收率=(吸收硒/摄入硒)×100%
表2钙吸收对比实验结果
组别 | 摄入钙(mg/d) | 粪钙(mg/d) | 吸收钙(mg/d) | 钙吸收率(%) |
Ⅰ | 50.0±2.3 | 34.8±2.1 | 15.2±1.6 | 30.3±3.0 |
Ⅱ | 49.2±2.0 | 27.7±1.4 | 21.6±2.6 | 43.7±3.9 |
Ⅲ | 49.6±2.6 | 25.2±1.6 | 24.4±2.3 | 49.1±3.0 |
由表2可知Ⅲ组钙吸收率高于Ⅱ组(P<0.01),Ⅱ组钙吸收率高于Ⅰ组(P<0.001)。
表3铁吸收对比实验结果
组别 | 摄入铁(mg/d) | 粪铁(mg/d) | 吸收铁(mg/d) | 铁吸收率(%) |
Ⅰ | 0.945±0.031 | 0.556±0.033 | 0.389±0.031 | 41.1±3.0 |
Ⅱ | 0.934±0.031 | 0.603±0.035 | 0.331±0.022 | 35.5±2.5 |
Ⅲ | 0.930±0.024 | 0.421±0.034 | 0.509±0.027 | 54.7±3.0 |
由表3可知Ⅲ组铁吸收率高于Ⅱ组(P<0.001),Ⅲ组铁吸收率高于Ⅰ组(P<0.001),Ⅱ组铁吸收率低于Ⅰ组(P<0.01)。
表4锌吸收对比实验结果
组别 | 摄入锌(mg/d) | 粪锌(mg/d) | 吸收锌(mg/d) | 锌吸收率(%) |
Ⅰ | 0.973±0.032 | 0.601±0.033 | 0.371±0.020 | 38.2±2.1 |
Ⅱ | 0.964±0.032 | 0.628±0.032 | 0.336±0.036 | 34.9±3.2 |
Ⅲ | 0.955±0.036 | 0.486±0.035 | 0.469±0.036 | 49.1±3.3 |
由表4可知Ⅲ组锌吸收率高于Ⅱ组(P<0.001),Ⅲ组锌吸收率高于Ⅰ组(P<0.001),Ⅱ组锌吸收率低于Ⅰ组(P<0.05)。
表5硒吸收对比实验结果
组别 | 摄入硒(μg/d) | 粪硒(μg/d) | 吸收硒(μg/d) | 硒吸收率(%) |
Ⅰ | 2.47±0.22 | 0.98±0.01 | 1.49±0.11 | 60.3±2.6 |
Ⅱ | 2.48±0.23 | 0.97±0.01 | 1.51±0.14 | 60.9±6.5 |
Ⅲ | 2.50±0.21 | 0.80±0.01 | 1.70±0.12 | 67.9±1.0 |
由表5可知Ⅲ组硒吸收率高于Ⅱ组(P<0.01),Ⅲ组硒吸收率高于Ⅰ组(P<0.01),Ⅰ组和Ⅱ组硒吸收率没有显著性差异。
综上,添加酪蛋白磷酸肽能够提高钙、铁、锌、硒的吸收率;维生素D能够提高钙吸收率,但是效果不如酪蛋白磷酸肽;维生素D对于铁、锌吸收有不利影响。
Claims (5)
1.一种儿童型钙铁锌硒多肽粉,其特征在于,按重量份数计包括以下组分:
2.如权利要求1所述的一种儿童型钙铁锌硒多肽粉的制备,其特征在于,按重量份数计还包括甜橙粉0.1-2.0份,柠檬酸0.5-2.0份,白砂糖40-80份,乳糖0.1-2.0份。
3.如权利要求1或2所述的一种儿童型钙铁锌硒多肽粉的制备,其特征在于,按重量份数计还包括L-乳酸钙0.9-1.7份。
4.一种如权利要求1-3任一所述的儿童型钙铁锌硒多肽粉的制备方法,其特征在于,包括步骤如下:
1)原辅料的处理,将葡萄糖酸钙、L-乳酸钙、葡萄糖酸锌、乳酸亚铁、酪蛋白磷酸肽、乳糖、白砂糖、柠檬酸、甜橙粉分别过100目筛,备用;
2)混合:在室内湿度为45-65%的条件下,先将亚硒酸钠和乳糖按配方量以等量递增法混合,得混合物A;再将混合物A与配方量的葡萄糖酸锌、L-乳酸钙、乳酸亚铁、酪蛋白磷酸肽、柠檬酸、甜橙粉混合20-40分钟,得混合物B;然后将混合物B与配方量的葡萄糖酸钙、白砂糖混合20-40min,得总混合物;
3)将混合物进行分装、包装入袋、经成品检验合格后入库。
5.如权利要求4所述的制备方法,其特征在于,步骤2)中亚硒酸钠和乳糖的混合具体为:取与亚硒酸钠等量的乳糖与亚硒酸钠混合均匀,得第一次混合物;再取与第一次混合物等量的乳糖与第一次混合物混合均匀,得第二次混合物;如此倍量增加,直至亚硒酸钠与乳糖全部混合均匀,得混合物A。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610640368.3A CN106262935A (zh) | 2016-08-05 | 2016-08-05 | 一种儿童型钙铁锌硒多肽粉 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610640368.3A CN106262935A (zh) | 2016-08-05 | 2016-08-05 | 一种儿童型钙铁锌硒多肽粉 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106262935A true CN106262935A (zh) | 2017-01-04 |
Family
ID=57665651
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610640368.3A Pending CN106262935A (zh) | 2016-08-05 | 2016-08-05 | 一种儿童型钙铁锌硒多肽粉 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106262935A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108185439A (zh) * | 2018-03-30 | 2018-06-22 | 河南爱心堂生物科技有限公司 | 一种补充锌硒元素的保健食品及其制备方法 |
CN108669403A (zh) * | 2018-05-28 | 2018-10-19 | 广州富诺营养科技有限公司 | 一种含铁锌钙多种维生素的泡腾片及其环形制剂与制备方法 |
CN109601679A (zh) * | 2019-01-10 | 2019-04-12 | 广州富诺健康科技股份有限公司 | 一种天然钙d软糖及其制备方法 |
-
2016
- 2016-08-05 CN CN201610640368.3A patent/CN106262935A/zh active Pending
Non-Patent Citations (1)
Title |
---|
牙套小王子: "绿健园牌钙铁锌硒多维片", 《首页>圈子》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108185439A (zh) * | 2018-03-30 | 2018-06-22 | 河南爱心堂生物科技有限公司 | 一种补充锌硒元素的保健食品及其制备方法 |
CN108669403A (zh) * | 2018-05-28 | 2018-10-19 | 广州富诺营养科技有限公司 | 一种含铁锌钙多种维生素的泡腾片及其环形制剂与制备方法 |
CN109601679A (zh) * | 2019-01-10 | 2019-04-12 | 广州富诺健康科技股份有限公司 | 一种天然钙d软糖及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102415447B (zh) | 一种适用于婴幼儿的补钙冲剂及其制备工艺 | |
CN106262935A (zh) | 一种儿童型钙铁锌硒多肽粉 | |
CN109329848A (zh) | 一种含低聚木糖的芝麻丸配方及制备方法 | |
CN106668507A (zh) | 一种用于治疗男性不孕不育的药物及其制备方法 | |
CN105768082A (zh) | 一种营养保健药膳粉 | |
CN101279089B (zh) | 阿胶钙组合物及其制备方法 | |
CN105878397A (zh) | 一种调节牛羊运输应激组合物 | |
CN104432099B (zh) | 一种含维生素k2的保健食品 | |
CN107183400A (zh) | 一种蛋鸡饲料 | |
CN105725013A (zh) | 一种无色的低糖型氨基酸饮品及其制备工艺 | |
CN105533699A (zh) | 一种儿童补锌与维生素组合物及其制备方法和应用 | |
CN102755393B (zh) | 一种治疗肝病的药剂及其制备方法 | |
KR20000065465A (ko) | 패각 추출물을 함유하는 기능성 음료 및 그의 제조방법 | |
CN103829046A (zh) | 一种低胆固醇、富铁、富钙鸡蛋的生产方法 | |
CN107495335A (zh) | 一种螯合钙组合物及其制备方法 | |
KR20040085848A (ko) | 고기능성 및 고품질 벌꿀의 생산방법 | |
CN109043547A (zh) | 一种螯合铁多维营养粉及其制备方法 | |
CN105920188A (zh) | 治疗营养性混合贫血的药物组合物、蜜丸及其制作方法 | |
KR20170065877A (ko) | 비타민 d 및 아연을 포함하는 액상의 건강기능식품 조성물 | |
CN106472420A (zh) | 一种低胆固醇、富维生素a、富维生素b2鸡蛋的生产方法 | |
CN106472417A (zh) | 一种低胆固醇、富镁、富维生素b2鸡蛋的生产方法 | |
CN101375893A (zh) | 用于预防出生缺陷并能改善记忆的药物组合物 | |
CN101375892A (zh) | 用于预防出生缺陷并能改善记忆的药物组合物 | |
CN101306046A (zh) | 用于预防出生缺陷与改善记忆的药物组合物 | |
CN101385751A (zh) | 用于预防出生缺陷并能改善记忆的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170104 |